Form 4: Day One Biopharmaceuticals Executive Sells Shares Under 10b5-1 Trading Plan

Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, sold 500 shares of common stock at an average price of $16.02, according to a Form 4 filing.

Summary

• Samuel C. Blackman, Head of R&D at Day One Biopharmaceuticals, filed a Form 4 with the SEC.
• The filing reports a sale of 500 shares of Day One Biopharmaceuticals common stock on October 31, 2024.
• The shares were sold at a weighted average price of $16.02 per share, with individual prices ranging from $16.00 to $16.05.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 10, 2023.
• Following the transaction, Blackman directly owns 1,097,035 shares of common stock.
• Blackman also indirectly owns 1,000,000 shares through the 2021 Blackman Family LLC, but disclaims beneficial ownership except to the extent of his and his wife's pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily reflect a change in the executive's view of the company.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• It is difficult to compare this transaction to industry standards without knowing the specific details of Blackman's compensation package and overall holdings.
• However, sales under 10b5-1 plans are common among executives at publicly traded companies, including those in the pharmaceutical industry such as Pfizer, Johnson & Johnson, and Merck.
• The size of the sale (500 shares) is relatively small compared to the total number of shares owned (1,097,035 directly and 1,000,000 indirectly).

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the impact is likely minimal given the small size of the transaction and the existence of a pre-arranged trading plan.

Key Dates